Biopharmaceutical giant AbbVie has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, along with associated intellectual property from West Pharmaceutical Services. This transaction aligns with AbbVie’s strategic commitment to invest over $10 billion in U.S. capital over the next decade to support innovation and expand critical manufacturing capacity.
Investment details and strategic goals
-
Capital allocation: AbbVie plans to invest more than $175 million to acquire, modernize, and fully integrate the site into its global manufacturing network.
-
Core technology: The acquisition includes the transfer of 3.5 mL on-body injector technology.
-
Therapeutic support: The facility will focus on producing delivery devices for AbbVie’s current and next-generation portfolio in immunology and neuroscience.
Economic impact and timeline The expansion is expected to bring approximately 200 new jobs to Arizona, adding to AbbVie’s U.S. workforce of nearly 30,000 employees. The transaction is anticipated to close in mid-2026, subject to customary closing conditions. This move strengthens AbbVie’s domestic manufacturing footprint, ensuring the reliable delivery of high-impact medicines to patients.